A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
To investigate superiority of SPM 962 over placebo in early Parkinson's disease patients in a
multi-center, placebo-controlled, double-blind study following once-daily multiple
transdermal doses of SPM 962 within a range of 4.5 to 36.0 mg (12-week dose
titration/maintenance period)